SCHEMBL23888684

SCHEMBL23888684

CC(C)n1cccc(C(=O)Nc2ccc(Oc3ccnc(-c4cnn(CCO)c4)c3)cn2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 18/20 0.49
▸ KIT P10721 8/20 0.49
▸ PDGFRA P16234 7/20 0.49
▸ AXL P30530 2/20 0.49
▸ PDGFRB P09619 7/20 0.48
▸ MET P08581 3/20 0.48
▸ KDR P35968 3/20 0.48
▸ FLT3 P36888 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23888680 0.91 CSF1R (0.50) CSF1RKITPDGFRAPDGFRBMET
SCHEMBL23900692 0.91 CSF1R (0.59) CSF1RKITPDGFRAAXLPDGFRB
SCHEMBL23900589 0.86 CSF1R (0.47) CSF1RKITPDGFRAAXLPDGFRB
SCHEMBL23900728 0.85 CSF1R (0.58) CSF1RKITPDGFRAPDGFRBMET
SCHEMBL23900587 0.85 CSF1R (0.58) CSF1RKITPDGFRAPDGFRBMET
SCHEMBL23900673 0.84 CSF1R (0.44) CSF1RKITPDGFRAAXLPDGFRB
SCHEMBL23900596 0.84 CSF1R (0.46) CSF1RKITPDGFRAAXLPDGFRB
SCHEMBL23888742 0.83 CSF1R (0.50) CSF1RKITPDGFRAPDGFRBMET
SCHEMBL26169919 0.83 CSF1R (0.44) CSF1RKITPDGFRAAXLPDGFRB
SCHEMBL23900711 0.83 AXL (0.49) CSF1RKITPDGFRAAXLPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 — — US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 — — US disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-29 — — CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 — — CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 — — CN disclosed
CN-115315422-B Amide compound and application thereof 和记黄埔医药(上海)有限公司 2023-11-07 — — CN disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 — — EP disclosed
CN-115315422-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2022-11-08 — — CN disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 — — WO disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, ASS1, NAT1 CSF1R 2941/4885KIT 2734/4885PDGFRA 3533/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 CSF1R 2941/4885KIT 2734/4885PDGFRA 3533/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC CSF1R 3035/4885KIT 2866/4885PDGFRA 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback